Related Experiment Video
Updated: Feb 7, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
GSK-3β, a double-edged sword in Nrf2 regulation: Implications for neurological dysfunction and disease
Megan Culbreth1, Michael Aschner2
1Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, 14642, USA.
Abstract:
In the past decade, it has become evident that glycogen synthase kinase 3β (GSK-3β) modulates the nuclear factor erythroid 2-related factor 2 (Nrf2) oxidative stress response. GSK-3β functions as an inhibitor, both directly in the activation and indirectly in the post-induction of Nrf2. The incidence of oxidative stress in neurological dysfunction and disease has made this signaling pathway an attractive therapeutic target. There is minimal evidence, however, to support a distinctive function for GSK-3β mediated Nrf2 inhibition in nervous system decline, apart from the typical oxidative stress response. In both Alzheimer's disease and brain ischemia, this pathway has been explored for potential benefits on disease etiology and advancement. Presently, it is unclear whether GSK-3β mediated Nrf2 inhibition markedly influences these disease states. Furthermore, the potential that each has unique function in neurodegenerative decline is unsubstantiated.
Insights
Glycogen synthase kinase 3β (GSK-3β) inhibits the Nrf2 oxidative stress pathway. Its distinct role in neurodegenerative decline, beyond general oxidative stress, remains unclear in conditions like Alzheimer's disease and brain ischemia.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Glycogen synthase kinase 3β (GSK-3β) is known to modulate the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.
- GSK-3β acts as an inhibitor of Nrf2 activation and post-induction.
- Oxidative stress is implicated in neurological dysfunction, making the Nrf2 pathway a therapeutic target.
Purpose of the Study:
- To investigate the specific role of GSK-3β mediated Nrf2 inhibition in neurological decline.
- To explore the influence of this pathway in Alzheimer's disease and brain ischemia.
- To determine if GSK-3β has a distinct function in neurodegeneration separate from general oxidative stress responses.
Main Methods:
- Literature review and analysis of existing studies on GSK-3β and Nrf2.
- Examination of evidence linking GSK-3β/Nrf2 pathway to Alzheimer's disease.
- Assessment of the pathway's role in brain ischemia models.
Main Results:
- Evidence suggests GSK-3β inhibits Nrf2, impacting oxidative stress response.
- The specific contribution of this inhibition to neurodegenerative diseases like Alzheimer's and ischemia is not well-established.
- A unique function of GSK-3β in neurodegeneration, beyond oxidative stress, is currently unsubstantiated.
Conclusions:
- The precise role of GSK-3β in modulating Nrf2 and its impact on neurodegenerative diseases requires further investigation.
- Clarifying GSK-3β's distinct functions in nervous system decline is crucial for therapeutic development.
- Current evidence does not conclusively support a unique role for GSK-3β mediated Nrf2 inhibition in neurodegeneration.
Related Concept Videos
Epigenetic Regulation
GTPases and their Regulation
Large G-proteins,...
Fixing Double-strand Breaks
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Master Transcription Regulators
Negative Regulator Molecules

